BioSpace News Archive

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring Systems, announces a landmark global collaboration with SNAQ, an award-winning app-based solution that offers key insights on food and nutrition for people with diabetes.

Syndax Pharmaceuticals, Inc. today announced that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023 , at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2022, and recent operational highlights.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Cowen 43rd Annual Healthcare Conference in Boston, MA.

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates.

Sensei Biotherapeutics, Inc. presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“ Miravo ” or the “ Company ”) reminds its shareholders (“ Shareholders ”) of its special meeting of Shareholders (the “ Meeting ”) to be held virtually on March 7, 2023.

Apyx Medical Corporation today announced that the Company and its subsidiaries have entered into a new, five-year secured credit facility with MidCap Financial.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 1, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

89bio, Inc. (Nasdaq: ETNB) today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans.